New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone inhaler for the regular treatment of asthma to be launched in the UK.

Image of both strengths of Seffalair Spiromax inhaler side by side.
Patients should be trained how to use Seffalair Spiromax and advised to inhale forcefully to ensure optimal dosing. | TEVA UK

Seffalair Spiromax contains the long-acting beta agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone. It is indicated for the regular treatment of asthma in patients not adequately controlled with ICS and 'as needed' inhaled short-acting β2 agonist.

The inhaler is available in two strengths, providing salmeterol/fluticasone propionate delivered doses of 12.75/100 microgram and 12.75/202 microgram. 

The Spiromax device, which is also available as Duoresp Spiromax (formoterol/budesonide, indicated in asthma and COPD), is breath-actuated dry powder inhaler that has a design similar to that of pressurised metered-dose inhalers.

There are three steps to using the Spiromax inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.

Sustainable option

As a dry powder inhaler, Seffalair Spiromax has a lower carbon footprint than pressurised metered dose inhalers (MDIs). MDIs have estimated carbon footprints of 500g CO2eq per dose, compared to 20g in dry powder inhalers, according to NICE. A patient decision aid published by NICE in 2019 recommends that prescribers and patients opt for the most environmentally friendly option when faced with a choice of suitable devices.

Want news like this straight to your inbox?
Sign up for our bulletins

Sandhiya Sodha recommends

MIMS Respiratory Clinic

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in